Adaptimmune taps Galapagos to decentralize manufacturing of solid tumor T cell therapy

Adap­ti­m­mune Ther­a­peu­tics and Gala­pa­gos have formed an al­liance to man­u­fac­ture a clin­i­cal-stage sol­id can­cer as­set in a de­cen­tral­ized way.

At the cen­ter of the deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.